bismuth
probabl
unknown
greek
roman
becam
familiar
middl
age
consid
metal
period
tabl
similar
semimet
rel
rare
element
earth
estim
natur
abund
part
per
million
bismuth
alway
byproduct
process
metal
ore
lead
silver
tin
copper
zinc
wide
use
variou
purpos
substitut
lead
bismuth
manufactur
industri
drawn
grow
attent
recent
term
resolv
environment
problem
caus
heavi
metal
pollut
bismuth
share
mani
characterist
lead
much
less
toxic
live
organ
nowaday
major
applic
bismuth
medicin
health
care
relat
high
effect
treat
varieti
diseas
caus
microbi
infect
potenti
activ
virus
tumor
develop
new
therapi
better
understand
mechan
action
bismuth
applic
metal
health
care
extend
bismuth
element
term
natur
abund
earth
crust
estim
world
bismuth
reserv
usual
base
content
lead
resourc
sinc
bismuth
often
byproduct
lead
product
tasna
mine
bolivia
mine
china
produc
bismuth
major
product
consumpt
bismuth
expand
fairli
rapidli
last
decad
approxim
ton
refineri
bismuth
produc
worldwid
among
countri
china
lead
produc
refin
bismuth
world
total
product
follow
mexico
belgium
peru
respect
estim
reserv
bismuth
world
shown
figur
comparison
major
heavi
metal
low
toxic
mark
bismuth
kind
green
element
environ
bismuth
compound
alloy
enjoy
widespread
commerci
applic
product
lubric
greas
chemic
catalyst
shot
bullet
cosmet
fire
sprinkler
system
solder
thermoelectr
materi
pigment
fish
sinker
u
u
carrier
medicin
malleabl
steel
etc
semimetal
crystal
structur
bismuth
along
physicalchem
properti
expans
solidif
widest
rang
melt
boil
point
among
metal
lowest
thermal
heat
conduct
make
bismuth
ideal
substitut
lead
analog
extremepressur
addit
ep
substitut
wide
use
leadbas
ep
addit
bismuthsulfur
addit
provid
higher
lubric
efficaci
also
reduc
half
amount
heavi
metal
use
extremepressur
lubric
accord
new
ecolog
environment
philosophi
world
recent
decad
substitut
lead
bismuth
glass
product
may
lead
potenti
applic
bismuth
manufactur
automobil
glass
finest
tablewar
art
object
purpos
environment
protect
north
america
bisn
use
replac
lead
shotshel
hunt
wetland
bird
although
bismuthcontain
shotshel
approv
nontox
comparison
high
toxic
lead
eg
toxic
intak
level
mg
kg
human
high
toler
bismuth
among
human
eg
toxic
intak
level
g
kg
human
render
rel
safe
substitut
prevent
environment
problem
caus
lead
accumul
owe
satini
luster
low
absorpt
properti
bismuth
compound
bismuth
oxychlorid
bismuth
vanad
also
use
cosmet
includ
nail
polish
lipstick
eye
shadow
recent
europ
restrict
hazard
substanc
direct
state
lead
must
elimin
manufactur
variou
type
electron
electr
equip
restrict
support
commerci
research
organ
japan
north
america
tend
increas
demand
bismuth
industri
futur
acceler
replac
process
lead
heavi
metal
bismuth
manufactur
industri
use
bismuth
drug
first
report
loui
odier
treatment
dyspepsia
nowaday
base
gradual
comprehend
characterist
element
mani
bismuth
compound
synthes
develop
new
medicin
treatment
mani
diseas
current
mani
bismuth
drug
mainli
use
antimicrobi
anticanc
agent
bismuth
compound
wide
use
treatment
variou
microbi
infect
syphili
sodiumpotassium
bismuth
tartrat
bismuth
quinin
iodid
iododbismitol
bismuth
chlorid
etc
coliti
bismuth
subnitr
bismuth
citrat
wound
infect
bismuth
oxid
quartan
malaria
sodium
bismuth
thioglycol
dyspepsia
bismuth
subsalicyl
bismuth
subnitr
etc
diarrhea
bismuth
subsalicyl
bismuth
nitrat
etc
peptic
ulcer
eg
colloid
bismuth
subcitr
bismuth
subsalicyl
bismuth
subnitr
bismuth
subsalicyl
bss
peptobismol
procter
gambl
compani
cincinnati
ohio
usa
wide
use
unit
state
treat
stomach
discomfort
travel
diarrhea
decad
bismuth
citratebas
compound
colloid
bismuth
subcitr
cb
denol
gist
brocad
astella
pharma
inc
ranitidin
bismuth
citrat
rbc
tritec
pylorid
glaxosmithklin
plc
use
treatment
gastrointestin
disord
therapeut
efficaci
bismuth
citratebas
drug
infect
helicobact
pylori
h
pylori
organ
first
discov
figur
may
attribut
antimicrobi
activ
bismuth
format
polymer
coat
ulcer
crater
prevent
eros
gastric
acid
figur
sinc
ranitidin
h
receptor
antagonist
compet
histamin
bind
h
receptor
induc
secret
stomach
acid
use
ranitidin
bismuth
citrat
rbc
antiulc
agent
prove
effici
newli
develop
bismuthbas
tripl
quadrupl
regimen
combin
bismuth
citratebas
drug
antibiot
amoxicillin
tetracyclin
clarithromycin
nitroimidazol
often
recommend
clinic
treat
h
pylori
infect
compar
normal
use
proton
pump
inhibitorbas
ppibas
tripl
therapi
bismuthbas
regimen
effici
first
second
thirdlin
h
pylori
erad
therapi
tabl
new
drug
bismuth
dpolygalacturon
acid
socal
colloid
bismuth
pectin
approv
clinic
use
china
treatment
peptic
ulcer
achiev
effect
similar
colloid
bismuth
subcitr
addit
current
use
bismuth
drug
newli
develop
bismuth
compound
also
exhibit
potenti
antimicrobi
activ
shown
antimicrobi
activ
bismuth
greatli
enhanc
bismuth
combin
thiolatecontain
organ
ligand
dimercaprol
dithiothreitol
complex
show
antimicrobi
activ
h
pylori
also
microorgan
staphylococcu
aureu
clostridium
difficil
minimum
inhibitori
concentr
mic
micromolar
level
although
thiolat
ligand
form
highli
stabl
complex
bismuth
ion
eg
format
constant
log
k
bismuth
glutathion
complex
thiolat
ligand
kinet
labil
exchang
free
thiol
millisecond
timescal
result
high
mobil
bismuth
ion
insid
cell
owe
intracellular
equilibrium
bismuth
ion
partial
releas
drug
exert
antimicrobi
role
sinc
nanotechnolog
extens
explor
recent
decad
bismuthbas
nanomateri
also
receiv
attent
pharmaceut
exampl
bismuth
subcarbon
bio
co
nanotub
exhibit
slightli
higher
activ
h
pylori
clinic
use
colloid
bismuth
subcitr
similar
condit
importantli
bismuth
nanotub
could
use
capsul
bismuthbas
tripl
quadrupl
therapeut
approach
toward
treatment
h
pylori
infect
drug
carrier
sustainedreleas
ingredi
human
bodi
use
combin
drug
treatment
diseas
bismuth
compound
found
exhibit
antitumor
activ
sever
cell
line
bismuth
thiolat
oxin
complex
exhibit
antitumor
activ
micromolar
concentr
mm
watersolubl
bismuth
cyclenbas
compound
bitpc
exhibit
anticanc
activ
time
potenc
cisplatin
cisdiamminedichloroplatinum
cddp
wide
use
anticanc
drug
probabl
via
interact
dna
physiolog
relev
condit
recent
shown
radioact
bismuth
bi
bi
exhibit
promis
potenti
novel
therapeut
agent
small
volum
tumor
bi
bi
seri
branch
decay
result
emiss
abparticl
although
halflif
bi
short
h
radioact
lead
pb
h
use
vivo
gener
bi
shortrang
penetr
mm
bismuth
radionuclid
reduc
nonspecif
irradi
normal
tissu
around
target
cell
furthermor
order
conduct
bismuth
site
diseas
effect
chelat
ligand
use
togeth
bismuth
radionuclid
type
combin
treatment
strong
chelat
ligand
conjug
monoclon
antibodi
fusion
protein
standard
treatment
tumor
via
modif
ligand
eventu
produc
bismuthradiolabel
complex
metal
radiolabel
complex
introduc
host
target
specif
cell
type
site
diseas
releas
aparticl
near
tumor
tissu
therebi
minim
damag
surround
normal
tissu
report
antivir
applic
bismuth
compound
except
bismuth
sodium
triglycollam
histor
use
treat
wart
recent
bismuth
discov
effect
inhibit
sever
acut
respiratori
syndrom
coronaviru
sarscov
ic
less
mm
potenti
target
bismuth
scv
ntpasehelicas
zinccontain
enzym
rna
cap
activ
control
viru
reproduct
bind
bismuth
may
induc
conform
chang
enzym
subsequ
affect
helicas
rnadna
unwind
activ
therebi
inhibit
viru
prolifer
figur
anoth
potenti
applic
bismuth
compound
reduct
side
effect
anticanc
drug
cisplatin
cisplatin
analog
carboplatin
oxaliplatin
use
clinic
worldwid
treat
cancer
howev
major
obstacl
widespread
use
cisplatinbas
drug
persist
sever
toxic
side
effect
major
doselimit
effect
nephrotox
includ
ubular
degener
loss
brush
border
necrosi
miner
tubular
epitheli
cell
renal
damag
caus
platinum
pt
mechan
platinum
nephrotox
may
similar
mercuri
hg
may
involv
deplet
thiolat
group
renal
tube
shown
bismuth
subnitr
abl
allevi
side
effect
cisplatin
without
affect
anticanc
activ
combin
bismuth
subnitr
citrat
greatli
enhanc
bismuth
protect
virtu
due
increas
absorpt
bismuth
kidney
therebi
significantli
induc
synthesi
renal
metallothionein
mt
cysteinerich
protein
play
key
role
protect
kidney
effect
heavi
metal
vivo
experi
show
pretreat
bismuth
compound
prior
cisplatin
therapi
greatli
reduc
mice
blood
urea
nitrogen
bun
level
defin
indic
renal
damag
compar
trial
without
bismuth
figur
protein
enzym
regard
potenti
target
bismuth
biolog
system
investig
bismuthprotein
interact
improv
understand
mechan
action
bismuth
also
provid
basi
design
effect
bismuth
agent
bismuth
found
bind
transferrin
iron
transport
protein
preferenti
clobe
carbon
co
asynergist
anion
transferrin
like
act
bismuth
transport
vehicl
satur
iron
blood
plasma
importantli
metalbound
transferrin
rapidli
recogn
transferrin
receptor
higher
affin
receptor
metalbound
transferrin
apoform
extracellular
condit
figur
although
human
serum
albumin
abund
protein
serum
mm
hypothes
target
bismuth
plasma
bismuth
associ
transferrin
rest
serum
albumin
indic
higher
select
bismuth
transferrin
lactoferrin
anoth
type
major
ironbind
protein
transferrin
famili
also
strongli
bind
bismuth
ion
bismuthbound
lactoferrin
abl
compet
ironbound
lactoferrin
membran
intracellular
provid
anoth
rout
bismuth
transport
histidinerich
protein
hpn
hpnlike
histidin
residu
respect
h
pylori
also
potenti
target
bismuth
ion
mutagenesi
experi
shown
h
pylori
hpn
gene
knockout
fourfold
suscept
bismuth
antiulc
drug
wildtyp
indic
protect
role
hpn
h
pylori
respons
bismuthbas
therapi
interact
bismuth
bi
enzym
relat
high
affin
cystein
residu
exampl
bismuth
inhibit
ureas
activ
probabl
block
enzym
activ
site
coordin
cystein
residu
entranc
activ
site
although
bismuth
consid
nontox
much
g
toler
adult
longterm
use
bismuth
may
result
side
effect
even
toxic
human
subject
besid
case
caus
occup
exposur
bismuth
manufactur
industri
poison
incid
occur
form
accident
deliber
overdosag
bismuth
drug
extent
bismuth
toxic
depend
individu
case
type
bismuth
compound
amount
absorb
still
clear
select
individu
develop
bismuth
toxic
patient
suffer
toxic
differ
bismuth
level
blood
syndrom
rare
bismuth
level
mgl
among
bismuthbas
regimen
use
insolubl
bismuth
compound
bismuth
oxychlorid
bismuth
subcarbon
relat
low
toxic
wherea
use
solubl
bismuth
organ
compound
bismuth
sodium
tartrat
tripotassium
dicitratobismuth
combin
use
bismuth
thiolatecontain
ligand
associ
high
toxic
neurotox
nephrotox
probabl
due
enhanc
uptak
solubl
bismuth
salt
human
bodi
also
suggest
oral
bismuth
drug
need
undergo
methyl
intestin
microb
enabl
absorb
absorb
bismuth
accumul
kidney
lung
spleen
liver
brain
muscl
elimin
urin
fece
via
bile
intestin
secret
clinic
depend
administr
time
bismuth
toxic
roughli
divid
acut
chronic
exposur
exposur
dose
caus
neurotox
gastrointestin
toxic
nephrotox
hepatotox
increas
bismuth
concentr
blood
spite
toxic
side
effect
allevi
discontinu
bismuth
therapi
bismuth
iodoform
paraffin
past
bipp
reduc
risk
bacteri
infect
render
deep
necrot
wound
caviti
clean
promot
develop
granul
tissu
wide
use
oral
maxillofaci
ent
surgeri
ear
nose
throat
surgeri
antisept
dress
howev
exampl
seriou
advers
effect
bipp
observ
clinic
patient
treat
bipp
one
case
patient
becam
acut
confus
gait
becam
unsteadi
indic
encephalopathi
caus
overdosag
bismuth
confirm
observ
toxic
level
bismuth
patient
serum
anoth
case
involv
use
bipp
cover
dura
mater
wound
remov
larg
basal
cell
carcinoma
patient
becam
confus
comatos
encephalopathi
confirm
observ
diffus
cerebr
edema
tomograph
scan
howev
upon
remov
bipp
patient
recov
deterior
pack
appli
mechan
intox
well
understood
till
probabl
caus
interfer
bismuth
oxid
metabol
central
nervou
system
bind
essenti
enzym
reduc
cerebr
blood
flow
colloid
bismuth
subcitr
cb
wide
use
treat
peptic
ulcer
diarrhea
toxic
effect
rare
report
clinic
low
amount
bismuth
absorb
gastrointestin
tract
case
nephrotox
overdosag
cb
tabl
one
case
even
gastric
lavag
perform
initi
boy
suffer
acut
renal
failur
arf
associ
uremia
oliguria
ingest
denol
tablet
cb
g
day
ingest
cb
day
bismuth
level
blood
urin
mgl
respect
treatment
periton
dialysi
urin
volum
increas
plasma
bun
creatinin
level
decreas
gradual
day
admiss
patient
recov
bismuth
level
blood
went
back
normal
cure
seriou
side
effect
caus
bismuth
overdosag
antidot
dpenicillamin
figur
propos
transport
bismuth
bi
transferrin
mediat
endocytosi
bismuth
firstli
bind
apotransferrin
bismuthtransferrin
complex
recogn
transferrin
receptor
ph
bismuthtransferrin
complex
intern
cell
releas
endosom
follow
final
releas
metal
protein
ph
acid
dmp
dimercaptosuccin
acid
dmsa
dimercaprol
test
anim
limit
clinic
trial
shown
dmp
dmsa
effect
allevi
bismuth
poison
due
strong
chelat
abil
bismuth
ion
